The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

NCT00392171 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma
Astrocytoma
Oligodendroglioma
Glioblastoma

Interventions

DRUG: Temozolomide

Sponsor

Merck Sharp & Dohme LLC